Crucell forges vaccine pact with Sanofi

The Dutch biotech Crucell will pocket a €10 million up front payment and up to €66.5 million in milestone payments after forging a collaboration and marketing deal with Sanofi Pasteur for its rabies monoclonal antibodies. Sanofi Pasteur has a well developed market for vaccines to combat pre- and post-exposure rabies.

"Adding a next generation rabies treatment to our well-established rabies product range will further position the company as a leading force to help prevent this fatal disease," said Wayne Pisano, the CEO of Sanofi Pasteur. The deal was announced this morning.

- see this release
- read the report from Thomson Financial

Suggested Articles

Moderna is entering an important time, its CEO says. And the company is doing so with a new finance chief from Big Biotech.

Not wanting to be left behind in the COVID-19 vaccine race, Europe is stepping up its efforts secure supplies if any immunizations prove effective.

The Trump administration has selected five COVID-19 vaccines for Operation Warp Speed, the NYT reports, with Big Pharma dominating the list.